



InPharmation

The official publication of the Pharmacy Department
Volume 2, Issue 1

Inside this issue:

Formulary Changes, Patient Safety Corner,	2
Regulatory Information and Dates to Remember	3

Staff Spotlight

Joyce Hills, CPHT



Favorite Scripture: "Oh taste and see that the Lord is good." Psalm 34:8

Favorite Quote: Know that all things come from above and I am thankful for the cross, not the wooden beam, but who was placed on it, the blood that was shared and who died for me, my Lord and Savior.

Mrs. Joyce, a member of the purchasing team, is the newest recipient of the Franciscan Service Award. She loves her family and she loves her "babies", which include the pharmacy staff and anyone she encounters throughout the day! Mrs. Joyce enjoys playing with her grandkids and great grandkids and sneaking in a bite of delicious seafood or a sweet snack. She would love to be an entrepreneur, and if given a chance, she would travel to the Holy Land or Paris.

Mrs. Joyce loves the holidays! If she could have any Christmas present, she would be debt free! She would also desire endless compassion for others. This Christmas, Mrs. Joyce will be spending time with her loved ones, enjoying the festivities, cooking, and eating turkey gumbo. Most importantly, this Christmas, Mrs. Joyce will remember to celebrate Jesus!

One thing is certain...Mrs. Joyce has a heart of gold!

New Clinical Service: Pharmacy in the ED

By Britney Ross, PharmD, BCPS

November is an exciting month for many people, as it marks the beginning of the holiday season. This November, the pharmacy department also had some exciting news as we have just expanded clinical services to the adult Emergency Department (ED) at Our Lady of the Lake Hospital (LOL). November 11, 2015, marked the beginning of our expanding role.

Jess and I will be your go to sources for any and all things Emergency Medicine. In our ever growing, ever changing role, we will provide various clinical services between the hours of 9am and 7:30pm, seven days a week and be an immediately available resource to ED practitioners including nurses, physicians, respiratory therapists, technicians, and midlevel providers.

Although this is a new venture for the ED and the pharmacy department at LOL, this is not a new concept for hospital pharmacies across the country. ASHP released a position statement in 2008 encouraging all hospital pharmacies to provide pharmacy services to the ED to ensure safe and effective patient care. While not providing specific service requirements, a consistent theme of collaboration with physicians, nurses, and other health-care providers is stressed. At LOL, we will be providing

direct patient care including attending emergency situations, answering drug information questions, and preparing STAT IV medications. Pharmacy attendance at code blue situations is not new; however, attendance at all level 1 and level 2 traumas, strokes, intubations, and other medical emergencies is a new role for pharmacy at LOL. We have integrated ourselves into the trauma and stroke teams, and demonstrated skills that will help other members of the team focus on the patient. In the few short weeks that we have been in the ED, we have greatly reduced the time it takes for a nurse to receive a medication after putting in a med request. We have stocked our satellite with various medications to ensure timely receipt of critical infusions including insulin, fosphenytoin, Kcentra, vasopressors, and antihypertensives. As members of the ED team become aware of our availability, they have recognized that we can serve as an expert drug information source and have begun to utilize us as such. So far, it has been a positive experience for both the ED and the pharmacy department, and we hope that our role continues to grow and expand into a well-established position at LOL.

	Britney Ross	Jess Ge
Pharmacy School	University of Houston	University of California, San Francisco
Residency Training	UMass Memorial Medical Center	Community Regional Medical Center
Specialty Training	Critical Care, UMass Memorial Medical Center	
Work Experience	Emergency Medicine Clinical Pharmacy Specialist, UMass Memorial Medical Center (Jul 13-Jul 15)	Internal Medicine Clinical Staff Pharmacist, LOL (Feb 14-Jun 15), Critical Care/Cardiology Clinical Staff Pharmacist, LOL (Jun 15-Nov 15)
Other Qualifications	Board Certified Pharmacotherapy Specialist	ED Clinical Pharmacist Pilot, LOL (Dec 14-Jan 15), Board Certified Pharmacotherapy Specialist

Added to formulary:

- Antiretrovirals:
 - ◊ Complera (Rilpivirine/ Tenofovir/Emtricitabine)*
 - ◊ Stribild (Elvitegravir/ Cobicistat/ Emtricitabine/Tenofovir)*
 - ◊ Triumeq (Dolutegravir/Abacavir/Lamivudine)
 - ◊ Hivid (Zalcitabine/Dideoxycytidine)*
 - ◊ Prezcoibix (Darunavir/Cobicistat)
 - ◊ Tybost (Cobicistat)
 - ◊ Agenerase (Amprenavir)*
 - ◊ Fortovase (Sawuinavir)*
- * These will be only purchased if the patient's own med is not available
- Anthelmintics:
 - ◊ Stromectol (Ivermectin)
- Other
 - ◊ Istodax (Romidepsin): Restricted to outpatient use only
 - ◊ Entyvio (vedolizumab): Restricted to outpatient use only

Newly added restrictions:

- Albenza (Albendazole): Restricted to use by ID physicians

Removed from formulary:

- Tindamax (Tinidazole)

New Therapeutic Interchanges:

- New interchange for long-acting bronchodilators will be Servent Diskus (salmeterol)
 - ◊ Foradil Aerolizer (formoterol) is being taken off the market
 - ◊ Change to occur when stock of Foradil Aerolizer runs out
- Vitamin K (phytonadione) oral solution will be interchanged for vitamin K (phytonadione) tablet
 - ◊ Change to occur when stock of vitamin K tablets runs out

IV to Po Update:


- IV levothyroxine to PO levothyroxine
 - ◊ Excludes myxedema coma

Ancobon (Flucytosine) update:

- Default order will be 25mg/kg every 6 hours
- Will be added to the dose rounding protocol
- Round up to the nearest 500mg capsule
- Will be added to the renal dosing protocol

Safety Opportunities:

Last month an error was found regarding a medication in the ER pyxis. Atracurium was found in the pyxis drawer where fosphenytoin was supposed to be stocked. Fortunately, this did not lead to patient harm because the ED pharmacist was able to catch the error prior to the medication being dispensed. The boxes for each of these drugs are very similar, please be cautious when checking vials like these that look similar!



Entresto:

Entresto is a new combination product that contains sacubitril and valsartan approved for patients with chronic heart failure. Entresto has been added to our formulary and will now be stocked, however it is restricted for use as a continuation of a patient's home medication only. When entering an order for Entresto ensure that the patient is not prescribed another ACE inhibitor or ARB concomitantly. If the patient was previously taking an ACE inhibitor, a 36 hour washout period is required between use of Entresto and the ACEi. A pop-up will be added to notify the verifying pharmacist of this required washout period; please carefully look at the patients' active and discontinued orders prior to verifying all orders for this new agent to ensure there is no overlap in use.

Antibiotic	Dose	Renal Adjustment	HD	CAPD	CRRT
Flucytosine	25mg/kg Q6H	CrCl 20-40: 25mg/kg Q12H	25 mg/kg Q48-72H; after HD	1000mg Q24H	25 mg/kg Q12
		CrCl10-20: 25mg/kg Q24H			
		CrCl <10: 25mg/kg Q48H			

Regulatory

Recent FDA Drug Approvals

- **Glycopyrrolate (Seebri Neohaler)** inhalation powder for oral inhalation use indicated for patients with chronic obstructive pulmonary disease.
- **Indacaterol and glycopyrrolate (Utibron Neohaler)** inhalation powder for oral inhalation use indicated for patients with chronic obstructive pulmonary disease.
- **Mepolizumab (Nucala)** injection for subcutaneous use indicated for add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
- **Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (Genvoya)** tablet for oral use indicated for treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older.
- **Cobimetinib (Cotellic)** tablet for oral use indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.
- **Osimertinib (Tagrisso)** tablet for oral use indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer, as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy.
- **Antihemophilic Factor [Recombinant], Pegylated (Adynovate)** lyophilized powder for solution for intravenous injection indicated in adolescent and adult patients (12 years and older) with hemophilia A (congenital factor VIII) deficiency
- **Daratumumab (Darzalex)** injection for intravenous use indicated for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy
- **Ixazomib (Ninlaro)** capsule for oral use indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

- **Nivolumab (Opdivo)** injection for intravenous use indicated for the treatment of patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy.
- **Influenza vaccine, adjuvanted (Fluad)** suspension for intramuscular injection indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. It is approved for use in persons 65 years of age and older.
- **Necitumumab (Portrazza)** injection for intravenous use indicated, in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer.
- **Elotuzumab (Empliciti)** injection for intravenous use indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies.

Clozapine REMS Program

The FDA has mandated that a single registry be used for clozapine. This registry can be found at clozapinerems.com. All pharmacists must create an account with the clozapine registry at clozapinerems.com as soon as possible. To do this, go to the site, and do the following:

1. Under the "Pharmacist" tab, select "Pharmacy Staff Enrollment"
2. Complete the enrollment form (use OLOL address, not your personal address), use DEA: AO3420027
3. Complete and sign the pharmacy staff attestation

The FDA announced prescribers and pharmacies will have additional time to complete certification for the Clozapine REMS program, the previous deadline being December 14th. The Clozapine REMS program and the FDA are working together to determine the new timeline for certification and full program implementation and will communicate updated deadlines as the information becomes available.

INPHARMATION EDITORIAL STAFF

Content Editor

Carli Nesheiwat, PharmD, BCOP

Page Editor

Jennifer Jones, PharmD, BCPS

Writing Staff

Ashley Joseph, PharmD

Brandi LaFrance, PharmD, BCPS

Katie Ducote, PharmD, BCPS

Kellee Brown, PharmD

Stephanie Chang, PharmD

Lauren Linder, PharmD

Reminders

Please remember to **RENEW** your LSHP membership this month! Baton Rouge area is the South Central Chapter. Please email Katie Ducote at katherine.ducote@ololrnc.com if you have any questions!

February: We will be hosting residency candidates for interviews. Please help the clinical team show our potential residents what a great workplace Our Lady of the Lake is and show our guests how glad we are to meet them.